PT2678679T - Utilização de tubulina acetilada como um biomarcador da resposta farmacológica a furazanobenzimidazolos - Google Patents
Utilização de tubulina acetilada como um biomarcador da resposta farmacológica a furazanobenzimidazolosInfo
- Publication number
- PT2678679T PT2678679T PT127048262T PT12704826T PT2678679T PT 2678679 T PT2678679 T PT 2678679T PT 127048262 T PT127048262 T PT 127048262T PT 12704826 T PT12704826 T PT 12704826T PT 2678679 T PT2678679 T PT 2678679T
- Authority
- PT
- Portugal
- Prior art keywords
- furazanobenzimidazoles
- biomarker
- drug response
- acetylated tubulin
- tubulin
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11155774 | 2011-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2678679T true PT2678679T (pt) | 2017-04-07 |
Family
ID=44065555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT127048262T PT2678679T (pt) | 2011-02-24 | 2012-02-21 | Utilização de tubulina acetilada como um biomarcador da resposta farmacológica a furazanobenzimidazolos |
Country Status (14)
Country | Link |
---|---|
US (2) | US9476889B2 (pt) |
EP (1) | EP2678679B1 (pt) |
JP (1) | JP6295081B2 (pt) |
CN (1) | CN103392130B (pt) |
AU (1) | AU2012219611C1 (pt) |
CA (1) | CA2824497A1 (pt) |
DK (1) | DK2678679T3 (pt) |
ES (1) | ES2621413T3 (pt) |
HK (1) | HK1191096A1 (pt) |
HU (1) | HUE032187T2 (pt) |
PL (1) | PL2678679T3 (pt) |
PT (1) | PT2678679T (pt) |
WO (1) | WO2012113802A1 (pt) |
ZA (1) | ZA201306086B (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2691533B1 (en) * | 2011-03-29 | 2017-04-05 | Basilea Pharmaceutica AG | Use of phospho-akt as a biomarker of drug response |
US10392920B2 (en) * | 2013-12-05 | 2019-08-27 | Schlumberger Technology Corporation | Method and system of quantitative cement evaluation using logging while drilling |
WO2015132931A1 (ja) * | 2014-03-06 | 2015-09-11 | 三菱重工業株式会社 | 電動移動体情報提供装置と電動移動体情報提供方法 |
EP3365680A1 (en) | 2015-10-22 | 2018-08-29 | Basilea Pharmaceutica International AG | Use of eb1 as a biomarker of drug response |
KR102648947B1 (ko) | 2017-04-26 | 2024-03-18 | 바실리어 파마슈티카 인터내셔널 리미티드 | 푸라자노벤즈이미다졸 및 이의 결정 형태의 제조 공정 |
EP3624790A1 (en) | 2017-05-16 | 2020-03-25 | Basilea Pharmaceutica International AG | Novel dosage principle for drugs useful for treating neoplastic diseases |
EP3713565A1 (en) * | 2017-11-20 | 2020-09-30 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
CN109053584B (zh) * | 2018-09-12 | 2022-03-18 | 南京大学 | 一类1,2-二芳基苯并咪唑衍生物的制备及其应用 |
WO2020058405A1 (en) * | 2018-09-20 | 2020-03-26 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
KR102503593B1 (ko) * | 2020-03-11 | 2023-02-24 | 연세대학교 산학협력단 | 항암제 내성 진단 또는 치료용 조성물 |
CN114902047A (zh) * | 2020-03-16 | 2022-08-12 | 株式会社漫丹 | T细胞淋巴瘤的指标的检测方法及其应用 |
WO2022053549A1 (en) | 2020-09-10 | 2022-03-17 | Basilea Pharmaceutica International AG | Use of c-myc as a biomarker of drug response |
WO2024010479A1 (en) * | 2022-07-06 | 2024-01-11 | I3S - Instituto De Investigação E Inovação Em Saúde, Associação | Tubulin acetylation and its associated post-translational modifications as biomarkers of response to treatment with taxol, taxanes and other microtubule stabilizing anti-cancer agents |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030095953A1 (en) * | 1999-11-12 | 2003-05-22 | Myles C. Cabot | Methods of reversing drug resistance in cancer cells |
US20050227300A1 (en) * | 2001-12-07 | 2005-10-13 | Atadja Peter W | Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors |
WO2004103994A1 (en) | 2003-05-23 | 2004-12-02 | Basilea Pharmaceutica Ag | Furazanobenzimidazoles |
WO2006102557A2 (en) * | 2005-03-22 | 2006-09-28 | The President And Fellows Of Harvard College | Treatment of protein degradation disorders |
EP2644199B1 (en) * | 2007-03-05 | 2017-10-11 | NewSouth Innovations Pty Limited | Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents |
KR20100072024A (ko) * | 2007-09-14 | 2010-06-29 | 메틸진 인크. | 히스톤 탈아세틸화 효소 hdac1, hdac2 및/또는 hdac3의 선택적 억제제 및 미세관 안정화제로의 암 병용 치료법 |
EP2459553B1 (en) * | 2009-07-27 | 2014-10-01 | Basilea Pharmaceutica AG | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases |
-
2012
- 2012-02-21 PT PT127048262T patent/PT2678679T/pt unknown
- 2012-02-21 EP EP12704826.2A patent/EP2678679B1/en active Active
- 2012-02-21 PL PL12704826T patent/PL2678679T3/pl unknown
- 2012-02-21 JP JP2013554872A patent/JP6295081B2/ja not_active Expired - Fee Related
- 2012-02-21 WO PCT/EP2012/052954 patent/WO2012113802A1/en active Application Filing
- 2012-02-21 CA CA2824497A patent/CA2824497A1/en not_active Abandoned
- 2012-02-21 US US13/983,887 patent/US9476889B2/en active Active
- 2012-02-21 ES ES12704826.2T patent/ES2621413T3/es active Active
- 2012-02-21 AU AU2012219611A patent/AU2012219611C1/en not_active Ceased
- 2012-02-21 CN CN201280010196.1A patent/CN103392130B/zh not_active Expired - Fee Related
- 2012-02-21 HU HUE12704826A patent/HUE032187T2/en unknown
- 2012-02-21 DK DK12704826.2T patent/DK2678679T3/en active
-
2013
- 2013-08-13 ZA ZA2013/06086A patent/ZA201306086B/en unknown
-
2014
- 2014-04-29 HK HK14104108.5A patent/HK1191096A1/zh not_active IP Right Cessation
-
2016
- 2016-10-14 US US15/294,157 patent/US10067120B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US9476889B2 (en) | 2016-10-25 |
AU2012219611A1 (en) | 2013-07-25 |
CN103392130A (zh) | 2013-11-13 |
CN103392130B (zh) | 2015-11-25 |
ZA201306086B (en) | 2014-04-30 |
US20140005237A1 (en) | 2014-01-02 |
US10067120B2 (en) | 2018-09-04 |
AU2012219611B2 (en) | 2016-03-03 |
NZ613022A (en) | 2015-11-27 |
PL2678679T3 (pl) | 2017-07-31 |
WO2012113802A1 (en) | 2012-08-30 |
JP2014511486A (ja) | 2014-05-15 |
DK2678679T3 (en) | 2017-04-24 |
ES2621413T3 (es) | 2017-07-04 |
HK1191096A1 (zh) | 2014-07-18 |
US20170122934A1 (en) | 2017-05-04 |
CA2824497A1 (en) | 2012-08-30 |
JP6295081B2 (ja) | 2018-03-14 |
HUE032187T2 (en) | 2017-09-28 |
AU2012219611C1 (en) | 2016-07-21 |
EP2678679B1 (en) | 2017-02-08 |
EP2678679A1 (en) | 2014-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1191096A1 (zh) | 乙酰化微管蛋白作為對呋咱並苯並咪唑類的藥物反應的生物標誌物的用途 | |
HK1210180A1 (en) | Derivatives of betulin | |
GB201104096D0 (en) | Production of graphene | |
HK1204604A1 (en) | Stereoselective total synthesis of noribogaine | |
HK1192323A1 (zh) | -微管蛋白作為對呋咱並苯並咪唑類的藥物反應的生物標誌物的用途 | |
HK1189056A1 (zh) | 作為藥物對呋咱並苯並咪唑響應的生物標記的用途 | |
ZA201306520B (en) | Use of phospho-akt as a biomarker of drug response | |
HK1185947A1 (zh) | 作為呋咱並苯並咪唑類藥物應答的生物標記的用途 | |
EP2776586A4 (en) | BIOMARKERS OF REACTION ON PROTEASOMAL INHIBITORS | |
HK1203355A1 (en) | Uses of 4-desferrithiocin analogs 4- | |
ZA201400248B (en) | Synthesis of cleistainthin a and derivatives thereof | |
SG2014011639A (en) | Measuring form changes of a substrate | |
PL2465868T3 (pl) | Ulepszenie produkcji lipidów | |
GB201002606D0 (en) | Production of fuels | |
EP2776043A4 (en) | BIOMARKERS OF REACTION ON PROTEASOMAL INHIBITORS | |
GB2488866B (en) | Use of GPS to detect repetitive motion | |
EP2684869A4 (en) | PREPARATION OF 3-MERCAPOTOPROPIONATES | |
EP2782902A4 (en) | DERIVATIVES FROM PHENOXYISOBUTTERIC ACID | |
EP2791349A4 (en) | SYNTHESIS OF N-ACETYL-D-NEURAMIC ACID | |
EP2702991A4 (en) | COMPOSITION OF ENTACOPONE | |
ZA201207838B (en) | Use of zirconium or of a zirconium-comprising mixture | |
GB201106098D0 (en) | Production of fuels | |
EP2663185A4 (en) | FESTIVE FIGHTING POTENTIAL OF CALEBIN A | |
TWM433471U (en) | Assembly structure of gear | |
GB201110310D0 (en) | Paperless point of sale |